{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-006719","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2022-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.073239+00:00","generated_at":"2026-06-26T01:48:15.081034+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Incyte Q1 2022 revenue $733M (+21%); Jakafi guidance raised; Opzelura uptake strong","bullets":["Total product & royalty revenues $728M (+20% YoY); GAAP net income $38M ($0.17 EPS); non-GAAP net income $123M ($0.55).","Jakafi net product rev $544M (+17% YoY); full-year guidance raised to $2.33-$2.40B from $2.3-$2.4B.","Opzelura >38,000 new patients in Q1; 146M lives covered; vitiligo sNDA under FDA review, PDUFA July 18.","Pemazyre approved in China; ruxolitinib QD NDA on track H1 2022; positive CHMP opinion for ruxolitinib in GVHD.","Cash, equivalents & securities $2.5B as of March 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-006719","json":"https://secwatch.observer/filing/0001558370-22-006719.json","markdown":"https://secwatch.observer/filing/0001558370-22-006719.md","text":"https://secwatch.observer/filing/0001558370-22-006719.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000155837022006719/0001558370-22-006719-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000155837022006719/incy-20220503x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T01:48:15.081034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}